Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort

CONCLUSION: First-line trastuzumab plus pertuzumab do not markedly diminish T-DM1's efficacy in second-line. Similarly, sequential treatment with trastuzumab plus pertuzumab then T-DM1 does not noticeably modify the efficacy of lapatinib plus capecitabine.PMID:35299035 | PMC:PMC8927850 | DOI:10.1016/j.breast.2022.03.004

Source: Breast - March 17, 2022 Category: Cancer & Oncology Authors: Fabien Moinard-Butot Caroline Saint-Martin Carole Pflumio Matthieu Carton William Jacot Paul-Henri Cottu V éronique Diéras Florence Dalenc Anthony Goncalves Marc Debled Anne Patsouris Marie-Ange Mouret-Reynier Laurence Vanlemmens Marianne Leheurteur Geo Source Type: research